Psychiatry Medication Follow-Up Titration

Psychiatrist Background & Purpose of Appointment This is a 4-week follow-up titration review for a 15-year-old male patient, Master J. Smith, who commenced methylphenidate 18mg modified release daily four weeks ago for ADHD. The primary aims of this appointment were to review his response to the medication, assess for any side effects, check adherence, and evaluate physical health monitoring findings to inform potential dose adjustments. Response to Medication Master Smith reports a noticeable improvement in his ability to focus during school lessons, stating he can now complete tasks more efficiently without getting easily distracted. His mother, Ms. Sarah Smith, corroborates this, noting a significant reduction in impulsive behaviours at home and improved organisational skills for homework. He feels the current dose is effective, describing less internal restlessness. He still experiences some difficulty initiating tasks, particularly less preferred ones, but overall, he feels more productive and attentive. No feedback from teachers was available for this review. Side Effects During the initial two weeks, Master Smith experienced a mild decrease in appetite around lunchtime, which has since resolved. He also reported some initial difficulty falling asleep on the first few nights, but this has improved with consistent medication timing and a pre-bedtime routine. He explicitly denies any other physical side effects such as headaches, stomach aches, or cardiovascular symptoms. Psychologically, he denies any changes in mood, irritability, or anxiety levels, stating he feels generally calm and focused on the medication. Adherence & Monitoring Master Smith has maintained excellent adherence to his prescribed methylphenidate, taking it daily as instructed. He uses a symptom tracker provided by the clinic to log his focus levels and any side effects, which was reviewed during the session. All doses have been taken without omission. His mother ensures he takes the medication in the morning. Physical parameters, as detailed below, remained within safe limits, and he understands the importance of ongoing monitoring for both efficacy and safety. Physical Health Monitoring Physical health parameters were obtained through home BP/pulse readings provided by the patient's mother, which were then corroborated using a validated device in the session. • Blood Pressure: 110/70 mmHg • Pulse: 72 bpm There was no evidence of cardiovascular compromise. Master Smith's weight has remained stable at 55 kg, with no reported changes in appetite since the initial adjustment period. No new medical concerns were raised, and his mother explicitly denied any other physical symptoms of concern. Mental State Examination Master Smith presented as a well-groomed, appropriately dressed 15-year-old male who appeared his stated age. He was cooperative and engaged throughout the session, maintaining good eye contact. • Appearance: Well-groomed, age-appropriate dress. • Behaviour: Calm, cooperative, no signs of restlessness or agitation, appropriate eye contact. • Speech: Spontaneous, normal volume and tone, coherent, goal-directed. • Mood (subjective): Reports feeling "good" and "more in control." • Affect (objective): Euthymic and congruent with reported mood. • Thought Process: Linear, coherent, and goal-directed. • Thought Content: No evidence of delusions, obsessions, or intrusive thoughts; denies any suicidal or self-harm ideation. • Perceptions: Denies any hallucinations or perceptual disturbances. • Cognition: Oriented to person, place, and time. Reported improved attention and memory for school tasks. No overt signs of cognitive impairment during the session. • Insight: Good understanding of his ADHD diagnosis, the role of medication in managing his symptoms, and the importance of ongoing monitoring. • Judgment: Good reasoning, decision-making, and safety awareness regarding his treatment and daily activities. Risk Assessment & Formulation Master Smith denied any current self-harm, suicidal ideation, or intent to harm others. He has no history of aggression or engagement in risky behaviours. No new risk factors were identified. • Predisposing factors: Family history of ADHD, diagnosed neurodevelopmental traits. • Precipitating factors: Initial struggles with academic demands and organisational tasks prior to medication initiation. • Perpetuating factors: None identified, as medication is proving effective. • Protective factors: Strong parental involvement and support, good insight into his condition, regular attendance at therapy sessions, stable home and school environment. Plan & Recommendations The outcome of the review indicates a positive response to methylphenidate 18mg with minimal, resolving side effects. To further optimise symptom control, the medication dose will be increased to methylphenidate 27mg modified release daily. The rationale for this dose adjustment is to address the residual difficulty with task initiation and aim for further improvements in attention and productivity, whilst remaining within safe and therapeutic limits. Master Smith and his mother were advised on potential signs of side effects, particularly noting any changes in appetite or sleep patterns, and instructed to continue home monitoring of BP and pulse. He was also advised to avoid excessive caffeine intake. The patient and his mother confirmed their understanding and agreement with the plan. The next review is scheduled for 1 November 2024 to reassess response to the new dose and monitor for any adverse effects.